Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Osteoarthritic Pain | Access and Reimbursement | US | 2018

Login to access report north_east
Contact sales account_box

Market Outlook

The U.S. treatment landscape for osteoarthritic (OA) pain, despite being highly genericized, contains a large number of brand-only agents, including multiple opioid analgesics with abuse-deterrent formulations (ADFs). In this analysis, DRG explores the current prescribing and reimbursement landscape for key branded analgesics, including what hurdles these agents—particularly opioid analgesic ADFs—face and how novel emerging therapies, including one of the first biologics for pain (Pfizer/Eli Lilly’s tanezumab), will be used. Additionally, this analysis offers insight into the role of surgical interventions as treatment alternatives for OA pain and to what extent such interventions are reimbursed.

QUESTIONS ANSWERED

  • What factors, including those tied to market access, influence physician prescribing of branded analgesics for OA pain, and what therapies are succeeding and stumbling based on these factors?
  • Which cost-control measures do payers use to manage the cost of branded analgesics for OA pain? What impact does pharmacoeconomic analysis have on formulary decisions for opioid analgesic ADFs?
  • How do physicians use surgical interventions (e.g., joint replacement surgery) to treat OA pain? What are payers’ polices on such interventions?
  • What access and reimbursement challenges will emerging analgesics from Pfizer/Eli Lilly (tanezumab), DepoMed/Grünenthal (cebranopadol), and Nektar Therapeutics (NKTR-181) face?

PRODUCT DESCRIPTION

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.

Markets covered: United States

Primary research:

  • Survey of 51 rheumatologists and 51 pain specialists in the United States.
  • Survey of 30 U.S. managed care organizations (MCO) pharmacy and medical directors (PDs/MDs).

Key companies: Purdue Pharma, Horizon Pharma, Pfizer, Eli Lilly, Janssen, DepoMed, Grünenthal, Iroko, Collegium Pharmaceutical, Flexion Therapeutics, Nektar Therapeutics

Key drugs: Butrans, celecoxib (Celebrex, generics), diclofenac sodium gel (Voltaren Gel, generics), Duexis, Embeda, Hysingla ER, Nucynta ER, OxyContin, Vimovo, Vivlodex, Xtampza ER, Zilretta, Zorvolex, tanezumab, cebranopadol, NKTR-181

Content highlights:

  • Reimbursement and contracting.
  • Access and prescribing.
  • Special topics.
  • Opportunities and challenges for emerging therapies.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east